TrialTheranostics2025

Optical molecular imaging in oral- and oropharyngeal squamous cell carcinoma using a novel uPAR-targeting near-infrared imaging agent FG001 (ICG-Glu-Glu-AE105): An explorative phase II clinical trial.

Amanda Oester Andersen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.